Luye Pharma Group Ltd.
Symbol: 2186.HK
HKSE
3.02
HKDMarkedspris i dag
19.2061
P/E-forhold
1.7660
PEG Ratio
11.36B
MRK Cap
- 0.00%
DIV Udbytte
Luye Pharma Group Ltd. (2186-HK) Årsregnskaber
Balance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 30442.4 | 8522.3 | 5544.3 | 5510.3 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 8899.94 | 2867.5 | 3220.5 | 3072.1 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 9083.1 | 2354.9 | 1783.7 | 1765.1 | ||||||||||||||||||||
balance-sheet.row.inventory | 3262.94 | 827.9 | 772.9 | 746.3 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 14658.34 | 3009.9 | 4658.7 | 5059.1 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 47624.65 | 10703.3 | 10785.8 | 10396.7 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 19926.44 | 5127.2 | 4909.1 | 4594.5 | ||||||||||||||||||||
balance-sheet.row.goodwill | 4170.88 | 1041.9 | 1003.4 | 985.4 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 25053.85 | 6317.9 | 5984.7 | 5441.8 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 29224.74 | 7359.8 | 6988.1 | 6427.2 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | 1699.95 | 1968.4 | -2106.4 | -2489.9 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 291.01 | 144.6 | 113.9 | 133.1 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 4815.04 | 187.4 | 3559.1 | 3520.4 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 55957.17 | 14787.4 | 13463.8 | 12185.4 | ||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 103581.81 | 25490.7 | 24249.6 | 22582.1 | ||||||||||||||||||||
balance-sheet.row.account-payables | 2864.67 | 767.2 | 559.9 | 570.9 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | 25899.19 | 5195.8 | 6839.8 | 5263.2 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 565.73 | 294.9 | 256.3 | 205.1 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 10671.39 | 3228.2 | 2264.7 | 4227.6 | ||||||||||||||||||||
Deferred Revenue Non Current | 264.72 | 103.6 | 175 | 209.4 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 94.99 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 10345.67 | 2193.4 | 2087.5 | 1496.1 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 13045.19 | 3824.4 | 3720.7 | 6138 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 223.17 | 70.6 | 38.5 | 42 | ||||||||||||||||||||
balance-sheet.row.total-liab | 52136.22 | 11962.2 | 13207.9 | 13468.2 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.common-stock | 1944.43 | 486.1 | 457 | 455.8 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | 14005.23 | 0 | 6667.3 | 6061.8 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 16081.52 | 7885.8 | 254.5 | 534 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 15700.8 | 4159.3 | 2797.3 | 1436.4 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 47731.99 | 12531.2 | 10176 | 8488.1 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 103581.81 | 25490.7 | 24249.6 | 22582.1 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 3713.61 | 997.3 | 865.8 | 625.8 | ||||||||||||||||||||
balance-sheet.row.total-equity | 51445.6 | 13528.5 | 11041.7 | 9113.9 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 103581.81 | - | - | - | ||||||||||||||||||||
Total Investments | 7732.43 | 1968.4 | 1114.1 | 582.2 | ||||||||||||||||||||
balance-sheet.row.total-debt | 36570.58 | 8423.9 | 9104.5 | 9490.8 | ||||||||||||||||||||
balance-sheet.row.net-debt | 18731.27 | 2769.1 | 6780.8 | 7052.5 |
Pengestrømsopgørelse
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 532.61 | 669.8 | -74.6 | 942.2 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 331.43 | 671.3 | 582 | 510.9 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | -914.59 | 0 | -311.9 | -505.9 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 20.64 | 25.4 | 50 | 50.9 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | 186.15 | 319.8 | -418.1 | -300.3 | |||||||||||||||||||
cash-flows.row.account-receivables | -403.05 | -18.8 | -211.8 | 145 | |||||||||||||||||||
cash-flows.row.inventory | -30.67 | -26.6 | -134 | 4.9 | |||||||||||||||||||
cash-flows.row.account-payables | 118.98 | 18.8 | 211.8 | -145 | |||||||||||||||||||
cash-flows.row.other-working-capital | 619.86 | 346.4 | -284 | -305.2 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | -381.1 | -32.5 | 355 | 335.7 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 689.73 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -544.22 | -1163.7 | -1541.6 | -1519.9 | |||||||||||||||||||
cash-flows.row.acquisitions-net | 0.11 | 0 | -808.5 | -450.8 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | -218.72 | -3485.9 | -3975.7 | -2859.2 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 627.68 | 2899.5 | 1919 | 4153.8 | |||||||||||||||||||
cash-flows.row.other-investing-activites | -78.02 | 91.8 | 970.7 | 814.2 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -78.02 | -1658.3 | -3436 | 138.2 | |||||||||||||||||||
cash-flows.row.debt-repayment | -561.84 | -8301.9 | -7536.7 | -5896.7 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 1043.83 | 189.2 | 1044.5 | 7326.7 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | -78 | |||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | -175.5 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 1522.95 | 8166.9 | 8371.1 | -922.6 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 1522.95 | 54.1 | 1878.9 | 254 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 14.37 | -164.1 | -52.4 | 112.4 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | 3254.94 | -114.5 | -1427.1 | 1538 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 5899.82 | 2323.7 | 2438.3 | 3865.4 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 2644.89 | 2438.3 | 3865.4 | 2327.3 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | 689.73 | 1653.8 | 182.4 | 1033.4 | |||||||||||||||||||
cash-flows.row.capital-expenditure | -544.22 | -1163.7 | -1541.6 | -1519.9 | |||||||||||||||||||
cash-flows.row.free-cash-flow | 145.51 | 490.1 | -1359.2 | -486.4 |
Resultatopgørelse række
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 6143.08 | 6143.1 | 5981.7 | 5200.2 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 1938.9 | 1938.9 | 1841.1 | 1803.5 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 4204.18 | 4204.2 | 4140.5 | 3396.7 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 586.16 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 643.97 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 2056.17 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0.3 | -73.3 | 155.2 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 3038.59 | 3175.4 | 3186.6 | 3113.9 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 4977.49 | 5114.4 | 5027.8 | 4917.4 | ||||||||||||||||||||
income-statement-row.row.interest-income | 465.49 | 117.1 | 88.7 | 102 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 347.02 | 675.5 | 471.8 | 399.5 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 2056.17 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -187.34 | -187.3 | -545.2 | -461.5 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0.3 | -73.3 | 155.2 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | -187.34 | -187.3 | -545.2 | -461.5 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 347.02 | 675.5 | 471.8 | 399.5 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 634.89 | 701.9 | 671.3 | 582 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | 1522.33 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | 887.44 | 887.4 | 1215 | 387 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | 700.1 | 700.1 | 669.8 | -74.6 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 161.02 | 161 | 86.5 | 70.2 | ||||||||||||||||||||
income-statement-row.row.net-income | 532.61 | 532.6 | 604.8 | -144.8 |
Ofte stillede spørgsmål
Hvad er Luye Pharma Group Ltd. (2186.HK) samlede aktiver?
Luye Pharma Group Ltd. (2186.HK) samlede aktiver er 25490715000.000.
Hvad er virksomhedens årlige omsætning?
Den årlige omsætning er 3238970000.000.
Hvad er virksomhedens profitmargin?
Virksomhedens profitmargin er 0.684.
Hvad er virksomhedens frie pengestrøm?
Det frie cash flow er 0.039.
Hvad er virksomhedens nettoprofitmargin?
Nettofortjenstmargenen er 0.087.
Hvad er firmaets samlede omsætning?
Den samlede omsætning er 0.144.
Hvad er Luye Pharma Group Ltd. (2186.HK) nettoresultat (nettoindkomst)?
Nettoresultatet (nettoindkomsten) er 532605000.000.
Hvad er virksomhedens samlede gæld?
Den samlede gæld er 8423947000.000.
Hvad er tallet for driftsudgifter?
Driftsudgifterne er 3175450000.000.
Hvad er firmaets likviditet?
Virksomhedens likviditet er 5654804000.000.